A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects With HF and Left Ventricular Systolic Dysfunction

Trial Profile

A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects With HF and Left Ventricular Systolic Dysfunction

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2017

At a glance

  • Drugs Omecamtiv mecarbil (Primary)
  • Indications Chronic heart failure; Left ventricular dysfunction
  • Focus Pharmacokinetics
  • Acronyms COSMIC-HF
  • Sponsors Amgen
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 May 2017 Results published in a Cytokinetics Media Release.
    • 01 May 2017 According to a Cytokinetics media release, results from this study were presented at Heart Failure 2017, the annual congress of the Heart Failure Association of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top